Detalles de la búsqueda
1.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet
; 395(10240): 1845-1854, 2020 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32450106
2.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
3.
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 389(10069): 621-628, 2017 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28017399
4.
Comparative study on fermentation performance in the genome shuffled Candida versatilis and wild-type salt tolerant yeast strain.
J Sci Food Agric
; 97(1): 284-290, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27012958
5.
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet
; 385(9984): 2272-9, 2015 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25817373
6.
A comparison of whole cell directed evolution approaches in breeding of industrial strain of Saccharomyces cerevisiae.
Biotechnol Lett
; 37(7): 1393-8, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25773199
7.
Non-targeted metabolomic reveals the effect of salt stress on global metabolite of halotolerant yeast Candida versatilis and principal component analysis.
J Ind Microbiol Biotechnol
; 41(10): 1553-62, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25085740
8.
Effect of salt-tolerant yeast of Candida versatilis and Zygosaccharomyces rouxii on the production of biogenic amines during soy sauce fermentation.
J Sci Food Agric
; 94(8): 1537-42, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24154976
9.
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Emerg Microbes Infect
; 13(1): 2281355, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933089
10.
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Lancet Infect Dis
; 23(10): 1143-1152, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37352880
11.
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
Lancet Respir Med
; 11(8): 698-708, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209700
12.
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Lancet Respir Med
; 11(7): 613-623, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898400
13.
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Lancet Reg Health West Pac
; : 100829, 2023 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37360864
14.
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Lancet Respir Med
; 10(8): 739-748, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605625
15.
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above.
Expert Rev Vaccines
; 21(12): 1843-1849, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048417
16.
Identification of salt-tolerant gene HOG1 in Torulopsis versatilis.
Biotechnol Lett
; 33(7): 1449-56, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21431849
17.
Correlation of ischemic ophthalmopathy with lacunar infarction.
Int J Ophthalmol
; 13(6): 960-964, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32566509
18.
[The experimental studies on cell transplantation into chronic ischemic myocardium using mesenchymal stem cells modified by recombinant adenovirus carrying vascular endothelial growth factors 165 gene].
Zhonghua Wai Ke Za Zhi
; 45(14): 990-3, 2007 Jul 15.
Artículo
en Zh
| MEDLINE | ID: mdl-17961389
19.
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Glob Health
; 5(3): e324-e334, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28017642
20.
In vitro assay for HCV serine proteinase expressed in insect cells.
World J Gastroenterol
; 9(7): 1629-32, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12854181